Clinical Trial Update: Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and immunogenicity of the DNA vaccine N-pVAX1 for Crimean-Congo hemorrhagic fever has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crimean-congo Hemorrhagic Fever

Drugs mentioned

• N-pVAX1 (N-pVAX1)

Snippet

Sponsor: Karolinska Institutet | Conditions: Crimean Congo Hemorrhagic Fever | Phase 1 | Status: COMPLETED